What is the market's earnings forecast for Beam Therapeutics next quarter?

What factors drove the changes in Beam Therapeutics's revenue and profit?

Did Beam Therapeutics beat or miss consensus estimates last quarter?

What guidance did Beam Therapeutics's management provide for the next earnings period?

What were the key takeaways from Beam Therapeutics's earnings call?

What were the key takeaways from Beam Therapeutics’s earnings call?

What is Beam Therapeutics's latest dividend and current dividend yield?

What is Beam Therapeutics's gross profit margin?

- **Breakthrough PKU Program**: BEAM-304 targets two common mutations, with preclinical data showing rapid Phe normalization and potential to treat nearly half of PKU patients. FDA supports an adaptive clinical trial design for multiple mutations.
- **$500M Financing for Sickle Cell**: Sixth Street funding extends Beam's runway to 2029, enabling risto-cel commercialization and pipeline advancement, including BEAM-302 and BEAM-304.
- **Platform Scalability**: Base editing's modular design allows efficient mutation-specific therapy development, with LNP manufacturing consistency across programs.
- **Regulatory Innovation**: FDA collaboration on umbrella trials and plausible mechanism pathways could accelerate approvals for ultra-rare diseases, informing PKU and other programs.

**【CEO Summary Section】**
- Beam Therapeutics announced a new base editing program for phenylketonuria (PKU), BEAM-304, targeting the two most common mutations (R408W and another prevalent mutation) affecting nearly half of PKU patients. The program leverages the company's lipid nanoparticle (LNP) delivery platform and aims to achieve significant and sustained phenylalanine (Phe) reduction.
- The company secured a $500 million strategic financing agreement with Sixth Street to support the commercialization of risto-cel, its sickle cell disease therapy, with $100 million upfront and up to $300 million in milestone-based funding.
- Beam highlighted its platform's modularity, enabling rapid development of mutation-specific therapies for PKU and other metabolic diseases, with a focus on predictable outcomes and scalable manufacturing.

**【CFO Financial Commentary】**
- Beam ended 2025 with $1.25 billion in cash, cash equivalents, and marketable securities. The Sixth Street facility extends the company's cash runway into mid-2029, supporting pipeline execution through key milestones, including risto-cel launch, BEAM-302 pivotal trials, and BEAM-304 IND filing.
- The company emphasized financial discipline and operational efficiency, with a focus on leveraging non-dilutive capital to fund growth and innovation across its pipeline.

**【Q&A Highlights】**
- **Regulatory Path and Mutation Expansion**: Gopi Shanker noted that additional PKU mutations could be added to the BEAM-304 program through rapid IND amendments, with the FDA supporting an umbrella clinical trial design. Amy Simon highlighted the potential for adaptive trial designs to accelerate development across mutations.
- **LNP Delivery and Platform Consistency**: John Evans confirmed that BEAM-304 uses the same LNP platform as other programs (e.g., BEAM-302), leveraging internal lipid expertise and GMP manufacturing capabilities. Preclinical data showed predictable editing thresholds for Phe reduction.
- **Sickle Cell Market Dynamics**: Giuseppe Ciaramella noted high demand for ex vivo therapies but highlighted risto-cel's differentiated profile, including a median mobilization cycle of one, positioning it for potential market leadership.
- **FDA Guidance and Ultra-Rare Diseases**: Kiran Musunuru discussed FDA openness to platform approvals under the plausible mechanism framework, particularly for ultra-rare diseases like urea cycle disorders, which could inform future PKU strategy.

Beam Therapeutics Inc.(BEAM)-20260224-2025 Q4 Earnings call transcript

Beam Therapeutics (BEAM)-5 Nov 24-2024 Q3 Earnings call transcript

Actual	-1.03	-0.69	-0.69	-1.69	-3.35	-1.23	-0.42	-0.95	-1.01	-1.02	-1.56	-0.54	-1.33	-1.08	-1.22	1.73	-1.21	-1.11	-1.17	-1.09	-1.24	-1	2.33
Forecast	-0.5056	-0.516	-0.546	-0.6629	-0.7388	-0.6356	-0.7245	-0.948	-0.8918	-1.1203	-1.2641	-1.3573	-1.3201	-1.4246	-1.3287	-0.6912	-1.4152	-1.1271	-1.1832	-1.2284	-1.1838	-1.1126	-0.9378
Surprise	-103.72%	-33.72%	-26.37%	-154.94%	-353.44%	-93.52%	+42.03%	-0.21%	-13.25%	+8.95%	-23.41%	+60.22%	-0.75%	+24.19%	+8.18%	+350.29%	+14.50%	+1.52%	+1.12%	+11.27%	-4.75%	+10.12%	+348.45%

BEAM

BEAM fundamentals

BEAM Q4 2025 Earnings

Earnings Call

You can ask Aime

BEAM

BEAM fundamentals

BEAM Q4 2025 Earnings

Earnings Call

BEAM Earnings Call Summary for Q4/20258:00 AM on Feb 24, 2026

BEAM Earnings Call Summary for Q2/20257:00 AM on Aug 5, 2025

BEAM Earnings Call Summary for Q1/20257:00 AM on May 6, 2025

BEAM Earnings Call Summary for Q4/2024 Mar 28, 2026

BEAM Earnings Call Summary for Q3/20248:30 AM on Nov 5, 2024

You can ask Aime